Antiparkinsonian efficacy of guanosine in rodent models of movement disorder

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Universitat de Barcelona > Patologia i Terapèutica Experimental > Articles publicats en revistes (Patologia i Terapèutica Experimental) > View document

To access the full text documents, please follow this link: http://hdl.handle.net/2445/121515

dc.contributor	Universitat de Barcelona
dc.contributor.author	Massari, Caio M.
dc.contributor.author	López-Cano, Marc
dc.contributor.author	Núñez, Fabiana
dc.contributor.author	Fernández Dueñas, Víctor
dc.contributor.author	Tasca, Carla I.
dc.contributor.author	Ciruela Alférez, Francisco
dc.date	2018-04-12T11:59:04Z
dc.date	2018-04-12T11:59:04Z
dc.date	2017-10-04
dc.date	2018-04-12T11:59:04Z
dc.identifier.citation	1663-9812
dc.identifier.citation	679448
dc.identifier.uri	http://hdl.handle.net/2445/121515
dc.description.abstract	Guanosine (GUO) is a guanine-based purine nucleoside with important trophic functions and promising neuroprotective properties. Although the neuroprotective effects of GUO have been corroborated in cellular models of Parkinson's disease (PD), its efficacy as an antiparkinsonian agent has not been fully explored in PD animal models. Accordingly, we evaluated the effectiveness of GUO in reversing motor impairments in several rodent movement disorder models, including catalepsy, tremor, and hemiparkinsonism. Our results showed that orally administered GUO antagonized reserpine-mediated catalepsy, reduced reserpine-induced tremulous jaw movements, and potentiated the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine in unilaterally 6-hydroxidopamine-lesioned rats. In addition, at 5 and 7.5 mg/kg, GUO inhibited L-DOPA-induced dyskinesia in rats chronically treated with a pro-dopaminergic agent. Overall, we describe the therapeutic potential of GUO, which may be effective not only for reversing parkinsonian motor impairments but also for reducing dyskinesia induced by treatment for PD.
dc.format	8 p.
dc.format	application/pdf
dc.language.iso	eng
dc.publisher	Frontiers Media
dc.relation	Reproducció del document publicat a: https://doi.org/10.3389/fphar.2017.00700
dc.relation	Frontiers in Pharmacology, 2017, vol. 8, p. 700
dc.relation	https://doi.org/10.3389/fphar.2017.00700
dc.rights	cc-by (c) Massari, Caio M. et al., 2017
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	http://creativecommons.org/licenses/by/3.0/es
dc.subject	Malaltia de Parkinson
dc.subject	Trastorns motors
dc.subject	Tremolor
dc.subject	Nucleòsids
dc.subject	Parkinson's disease
dc.subject	Movement disorders
dc.subject	Tremor
dc.subject	Nucleosides
dc.title	Antiparkinsonian efficacy of guanosine in rodent models of movement disorder
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion

Show simple item record

All of RECERCAT

This Collection

Statistics

My RECERCAT

Related documents

Other documents of the same author